Connect Biopharma Holdings Limited (CNTB) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
CNTB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CNTB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -86.2% | -60.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export CNTB earnings history in CSV or JSON format
Free sign-in required to download data
Connect Biopharma Holdings Limited (CNTB) Earnings Overview
As of May 8, 2026, Connect Biopharma Holdings Limited (CNTB) reported trailing twelve-month net income of -$57M, reflecting +74.1% year-over-year growth. The company earned $-1.03 per diluted share over the past four quarters, with a net profit margin of -60.0%.
Looking at the long-term picture, CNTB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2024, representing a new all-time high.
Connect Biopharma Holdings Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ABBV ($4.23B net income, 6.9% margin), REGN ($4.42B net income, 31.4% margin), ARQT (-$2M net income, -4.3% margin), CNTB has room to improve margins relative to the peer group. Compare CNTB vs ABBV →
CNTB Earnings vs Peers
Earnings metrics vs comparable public companies
CNTB Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$16M | +73.7% | -$22M | $-0.28 | -60.0% | -86.2% |
| 2023 | -$60M | +48.9% | -$62M | $-1.08 | - | - |
| 2022 | -$116M | +43.3% | -$118M | $-14.50 | - | - |
| 2021 | -$205M | -70.6% | -$99M | $-25.00 | - | - |
| 2020 | -$120M | -400.8% | -$30M | $-14.45 | - | - |
| 2019 | -$24M | - | -$16M | $-3.02 | - | - |
See CNTB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCNTB — Frequently Asked Questions
Quick answers to the most common questions about buying CNTB stock.
Is CNTB growing earnings?
CNTB EPS is $-1.03, with earnings growth accelerating to +74.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-57M.
What are CNTB's profit margins?
Connect Biopharma Holdings Limited net margin is -60.0%, with operating margin at -86.2%. Below-average margins reflect competitive or cost pressures.
How consistent are CNTB's earnings?
CNTB earnings data spans 2019-2024. The accelerating earnings trend is +74.1% YoY. Historical data enables comparison across business cycles.